Abstract: The present invention relates to novel multi-specific antibodies comprising fine tuned combination of low affinity single binding domain fragments to selectively target double targets on cancer cell, and use thereof for therapy, such as for guided immunotherapy.

Abstract: Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

Abstract: Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

Abstract: Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.

Abstract: Fusion proteins comprising a portion of the HIV-1 Env protein and ScFv of an enhancing antibody are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection. A broadly neutralizing antibody and engineered bi-/tri-specific anti-HIV-1 antibodies that may serve in the prevention and/or treatment of HIV-1 infections in a subject are also disclosed, as well as methods of using the fusions proteins and antibodies.

Abstract: The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).

Abstract: The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).

Abstract: A 400 kA high energy efficiency reduction pot, comprising: anode carbon blocks, anode busbars, crust breaking and feeding device, anode lifting device, girders and pillars, pot hooding and exhausting system, cathode busbar arrangement structure, cathode carbon blocks, cathode lining structure and cathode pot shell, the pot is characterized in that: 1) superstructure and portal-type pillars are supported by pipe truss girders structure; 2) anode carbon block has eight steel stubs to be configured in a symmetrical mode; 3) the superstructure has 24 double-anode assemblies or 48 single-anode assemblies, six alumina feeding points, and two fluoride salt feeding points; 4) sub-section fume collecting and exhausting system is installed between a horizontal hood plate and a feeding hopper; 5) a device for sealing the anode rod by means a negative pressure suction is provided; 6) a new lining structure of holding heat on bottom, dispersing heat from side, and adding expansion layer at the cathode end have been design

Abstract: This invention relates to an in vitro method of producing antigen specific B cells and antibodies that provides for the capture of an entire primary human antibody repertoire for any foreign antigen, allows for screening large numbers of immunogen/adjuvant combinations, and permits the isolation of human monoclonal antibodies on demand thereby obviating the need to immunize humans with the target antigen.